Le fonds Nov Santé Actions Non Cotées, géré par Eurazeo, dédié au développement des filières de santé en France et lancé à l’initiative de France Assureurs et de la Caisse des Dépôts, est heureux d’annoncer la finalisation de son investissement de 23M€ dans le cadre de la réorganisation du capital d’Horus Pharma, laboratoire pharmaceutique français spécialisé dans l’ophtalmologie.
Click here to read the press release
Bridgepoint Group Limited, the UK based private equity firm, through its UK based indirect subsidiary Actium Bidco (UK) Limited, has …
Bridgepoint Group Limited, the UK based private equity firm, through its UK based indirect subsidiary Actium Bidco (UK) Limited, has …
Wakeo, the France based provider of a SaaS platform providing real-time visibility on international transport flows (sea, air, road) to …
Bregal Unternehmerkapital GmbH, the Germany based private equity firm, through Gemini BidCo, a special purpose vehicle indirectly controlled by the …
DeepForm Limited, the UK based company, that specializes in developing and offering novel press tool designs, which help reduce material …
Neuromedex, the Germany based provider of disposable products for neurosurgery and intensive care, has been acquired by Pinova Capital GmbH, …
